Adaptimmune Therapeutics plc
ADAP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $91 | $144 | $108 | $150 |
| Short-Term Investments | $60 | $3 | $97 | $220 |
| Receivables | $16 | $47 | $38 | $34 |
| Inventory | $7 | $0 | $0 | $0 |
| Other Curr. Assets | $13 | $14 | $13 | $12 |
| Total Curr. Assets | $188 | $208 | $255 | $415 |
| Property Plant & Equip (Net) | $51 | $72 | $72 | $51 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $4 | $0 | $0 | $1 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $3 | $2 | $2 |
| Total NC Assets | $58 | $75 | $74 | $54 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $246 | $283 | $329 | $470 |
| Liabilities | – | – | – | – |
| Payables | $9 | $8 | $5 | $8 |
| Short-Term Debt | $9 | $5 | $5 | $5 |
| Tax Payable | $0 | $1 | $0 | $0 |
| Deferred Revenue | $12 | $29 | $24 | $22 |
| Other Curr. Liab. | $34 | $29 | $21 | $24 |
| Total Curr. Liab. | $65 | $73 | $65 | $63 |
| LT Debt | $69 | $20 | $20 | $23 |
| Deferred Rev, NC | $96 | $149 | $161 | $177 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $4 | $1 | $1 | $1 |
| Total NC Liab. | $170 | $170 | $183 | $201 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $24 | $25 | $23 | $25 |
| Total Liabilities | $234 | $243 | $247 | $264 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $2 | $2 | $1 | $1 |
| Retained Earnings | -$1,094 | -$1,023 | -$909 | -$744 |
| AOCI | -$2 | -$4 | -$1 | -$11 |
| Other Equity | $1,106 | $1,065 | $991 | $960 |
| Total Equity | $12 | $40 | $82 | $206 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $246 | $283 | $329 | $470 |
| Net Debt | -$12 | -$119 | -$82 | -$122 |